Peer reviewed
Tesamorelin, a Growth Hormone-Releasing Hormone Analog, Reduces HIV Visceral Adiposity
Pivotal Phase 3 randomized trial (Falutz et al., 2010; PMID 20879920) showing tesamorelin significantly reduced visceral adipose tissue (VAT) over 26 weeks in HIV-infected patients with lipodystrophy. This trial supported FDA approval of Egrifta.
New England Journal of MedicinePublished 2010-09-02Accessed 2026-07-01
Registry record
Source metadata
- Publisher
- New England Journal of Medicine
- Source type
- Peer reviewed
- Registry ID
nejm-tesamorelin-phase3-2010
Source usage
Linked from 7 pages
Compound
Tesamorelin
ComparisonCJC-1295 + Ipamorelin vs Tesamorelin
ComparisonSermorelin vs Tesamorelin
Evidence curationBest Peptides for Growth Hormone Release
GuidePeptide Category Explainers: How Every Compound Class on This Site Is Defined
GuidePeptide Half-Life Reference Table
Research hubCompounded Peptides Explained: 503A vs 503B
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.